Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 May;77(9):1480–1486. doi: 10.1038/bjc.1998.243

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

M J Mackean 1, J Cassidy 1, D I Jodrell 1, J Paul 1, N S Reed 1, P A Canney 1, H Yosef 1, T Habeshaw 1, A G Robertson 1, A McInnes 1, C J Twelves 1
PMCID: PMC2150187  PMID: 9652765

Abstract

We have used a relatively new trial methodology, the group sequential design, to prospectively evaluate two dose levels of bolus/infusional 5-fluorouracil (5-FU) and folinic acid in 192 consecutive-patients with advanced colorectal carcinoma. On day 1, all patients received 200 mg m(-2) of folinic acid infusion over 2 h. Cohort A (n = 102 patients) received 500 mg m(-2) 5-FU by i.v. 15-min infusion followed by an infusion of 500 mg m(-2) 5-FU over 22 h. Treatment was repeated on day 2 and further cycles given 2-weekly. After sequential analysis excluded a response rate of over 40%, cohort B (n = 90 patients) received an increased dose of 600 mg m(-2) 5-FU bolus and infusion. Patients had received no prior 5-FU therapy and the two cohorts had similar demographic features. In 179 evaluable patients, the overall response rate was 18% (95% CI 12-24%) with CR of 6% and PR of 12%, with no difference between the two cohorts. Overall median survival was 34 weeks (95% CI 30-39) with no significant difference between cohorts (median survival 32 and 37 weeks in cohort A and B respectively; P = 0.27). On multivariate analysis, poor performance status, elevated initial WBC and alkaline phosphatase and low serum albumin were associated with reduced survival (P < 0.05), and initial raised WBC showed an association with reduced likelihood of response (P = 0.002). Overall toxicity was low with CTC grade 3 mucositis, diarrhoea, nausea or vomiting in < or = 6% of patients and no treatment-related deaths. Significant (grade 3 or above) leucopenia was more common in cohort B than in cohort A (9% and 1% respectively); there were more dose reductions, and the median administered dose intensity was lower in cohort B than in cohort A (89% and 97% respectively; P = 0.006). In this group of relatively unselected patients, we have confirmed a relatively low objective response rate and median survival of 7.8 months with this regimen. There was no significant difference in outcome between the two dose levels but the higher dose of 5-FU was associated with more dose reductions and greater toxicity.

Full text

PDF
1480

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bellissant E., Bénichou J., Chastang C. The group sequential triangular test for phase II cancer clinical trials. Am J Clin Oncol. 1996 Aug;19(4):422–430. doi: 10.1097/00000421-199608000-00021. [DOI] [PubMed] [Google Scholar]
  2. Bécouarn Y. H., Brunet R. C., Rouhier M. L., Bussières E. J., Avril A. R., Richaud P. M., Dilhuydy J. M. High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer. Cancer. 1995 Oct 1;76(7):1126–1131. doi: 10.1002/1097-0142(19951001)76:7<1126::aid-cncr2820760705>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  3. De Gramont A., Krulik M., Cady J., Lagadec B., Maisani J. E., Loiseau J. P., Grange J. D., Gonzalez-Canali G., Demuynck B., Louvet C. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1499–1503. doi: 10.1016/0277-5379(88)90341-0. [DOI] [PubMed] [Google Scholar]
  4. Dieras V., Extra J. M., Bellissant E., Espie M., Morvan F., Pierga J. Y., Mignot L., Tresca P., Marty M. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol. 1996 Dec;14(12):3097–3104. doi: 10.1200/JCO.1996.14.12.3097. [DOI] [PubMed] [Google Scholar]
  5. Graf W., Påhlman L., Bergström R., Glimelius B. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer. 1994 Sep;70(3):559–563. doi: 10.1038/bjc.1994.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hanna C. L., McKinna F. E., Williams L. B., Morrey D., Adams M., Mason M. D., Maughan T. S. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients. Br J Cancer. 1995 Sep;72(3):774–776. doi: 10.1038/bjc.1995.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jodrell D. I., Murray L. S., Reed N. S., Canney P. A., Kaye S. B., Cassidy J. Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? Br J Cancer. 1994 Oct;70(4):749–752. doi: 10.1038/bjc.1994.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Johnson P. W., Thompson P. I., Seymour M. T., Deasy N. P., Thuraisingham R. C., Slevin M. L., Wrigley P. F. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer. 1991 Sep;64(3):603–605. doi: 10.1038/bjc.1991.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  10. Petrelli N. J. It is time to stratify with prognostic factors for hepatic metastases. J Clin Oncol. 1995 Sep;13(9):2471–2472. doi: 10.1200/JCO.1995.13.9.2471. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES